江苏亚虹医药科技股份有限公司 2022 年限制性股票激励计划预留授予激励对象名单 （截止预留授予日） 一、 2022 年限制性股票激励计划预留授予的分配情况 序号 姓名 国籍 职务 获授的限制 性股票数量 （万股） 占授予限制 性股票总数 的比例 占本次激励计划 预留授予日股本 总额的比例 一、董事、高级管理人员 / / / / / / / 二、核心技术人员 / / / / / / / 三、其他激励对象 董事会认为需要激励的其他人员 ——中国籍员工（15 人） 77.50 7.88% 0.14% 董事会认为需要激励的其他人员 ——外籍员工（3 人） 115.00 11.70% 0.20% 预留授予授出小计 192.50 19.58% 0.34% 四、预留授予未授出部分 4.22 0.43% 0.01% 合计 196.72 20.01% 0.35% 注： 1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未超过公司股 本总额的 1%。公司全部有效期内的股权激励计划所涉及的标的股票总数累计不超过股权激励计划提交 股东大会审议时公司股本总额的 20%。 2、本次激励计划预留授予的激励对象不包 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2023-018 1、公司监事会对公司 2022 年限制性股票激励计划（以下简称"本次激励计 划"）预留部分限制性股票的授予条件是否成就进行核查，认为： 公司不存在《上市公司股权激励管理办法》（以下简称"《管理办法》"） 等法律、法规和规范性文件规定的禁止实施股权激励计划的情形，公司具备实施 股权激励计划的主体资格；本次激励计划预留授予的激励对象具备《中华人民共 和国公司法》等法律法规和规范性文件规定的任职资格，符合《管理办法》及《上 海证券交易所科创板股票上市规则》规定的激励对象条件，符合公司《2022年限 制性股票激励计划》及其摘要规定的激励对象范围，其作为公司本次激励计划预 1 留授予激励对象的主体资格合法、有效。公司2022年限制性股票激励计划规定的 预留授予条件已经成就。 江苏亚虹医药科技股份有限公司 第一届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏亚虹医药科技股份有限公司（以下简称"公司"）第一届 ...

北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2022 年限制性股票激励计划预留授予事项的 法律意见书 号所 LAW OFFICES 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 E United States Fi YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:江苏亚虹医药科技股份有限公司 北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2022 年限制性股票激励计划预留授予事项的法律意见书 嘉源(2023)-05-277 敬启者: 北京市嘉源律师事务所(以下简称"本所")接受江苏亚虹医药科技股份有 限公司(以下简称"亚虹医药"或"公司")的委托,担任亚虹医药实施2022年 限制性股票激励计划(以下简称"本激励计划")的专项法律顾问,就本激励计 划预留授予限制性股票事项(以下简称"本次授予")出具法律意见书。 本法律意见书系依据《中华人民共和国公司法》(以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券 ...

证券简称：亚虹医药 证券代码：688176 上海荣正企业咨询服务（集团）股份有限公司 关于 江苏亚虹医药科技股份有限公司 2022 年限制性股票激励计划 预留授予相关事项 之 独立财务顾问报告 2023 年 8 月 | | | 一、释义 3 / 12 1. 上市公司、公司、亚虹医药：指江苏亚虹医药科技股份有限公司。 2. 股权激励计划、限制性股票激励计划、本激励计划、激励计划、本计划：指 《江苏亚虹医药科技股份有限公司 2022 年限制性股票激励计划（草案）》。 3. 限制性股票、第二类限制性股票：指符合本激励计划授予条件的激励对象，在 满足相应归属条件后分次获得并登记的公司股票。 4. 股本总额：指公司股东大会审议通过本计划时公司已发行的股本总额。 5. 激励对象：指按照本激励计划规定，获得限制性股票的董事、高级管理人员、 核心技术人员及董事会认为需要激励的其他人员。 6. 授予日：指公司向激励对象授予限制性股票的日期。 7. 授予价格：指公司授予激励对象每一股限制性股票的价格。 8. 有效期：指从限制性股票首次授予之日起到激励对象获授的限制性股票全部归 属或作废失效的期间。 9. 归属：指激励对象满足获益 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2023-019 江苏亚虹医药科技股份有限公司 关于向 2022 年限制性股票激励计划激励对象 授予预留部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 江苏亚虹医药科技股份有限公司《2022 年限制性股票激励计划》（以下简称 "《激励计划》"或"本次激励计划"或"本激励计划"）规定的公司 2022 年 限制性股票预留授予条件已经成就，根据江苏亚虹医药科技股份有限公司（以下 简称"公司"）2022 年第一次临时股东大会的授权，公司于 2023 年 8 月 8 日召 开第一届董事会第十九次会议、第一届监事会第十七次会议，审议通过了《关于 向 2022 年限制性股票激励计划激励对象授予预留部分限制性股票的议案》，确 定 2023 年 8 月 8 日为预留授予日，以 6.79 元/股的授予价格向 18 名激励对象授 予 192.50 万股限制性股票。现将有关事项说明如下： 一、限制性股票授予情况 （一）本次限制性股票授予已履行的决策程序和信 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 22,874.40, representing a 150% increase compared to the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 62,934,818.04, with a basic and diluted earnings per share of -CNY 0.11[4] - Total operating revenue for Q1 2023 was ¥22,874.40 million, a significant increase from ¥9,149.76 million in Q1 2022, representing a growth of approximately 150%[17] - Net profit for Q1 2023 was -¥62,934.82 million, worsening from -¥47,294.45 million in Q1 2022, reflecting a decline of approximately 33%[18] - Basic and diluted earnings per share for Q1 2023 were both -¥0.11, compared to -¥0.08 in Q1 2022[18] Research and Development - Research and development expenses totaled CNY 56,872,414.28, accounting for 37.86% of the revenue[5] - Research and development expenses for Q1 2023 were ¥56,872.41 million, up from ¥41,253.05 million in Q1 2022, marking an increase of approximately 38%[17] - The increase in net loss was primarily due to an increase in employee numbers and sustained high R&D investment[7] - The company’s core products are still under development, with revenue generated only from specific clinical needs in Hainan Boao Lecheng International Medical Tourism Pilot Zone[5] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,809,688,194.04, a decrease of 2.23% from the end of the previous year[5] - The total current assets decreased to ¥2,689,750,874.13 from ¥2,760,086,589.05, indicating a decline of about 2.6%[14] - The company's total assets as of March 31, 2023, were ¥2,809,688,194.04, down from ¥2,873,779,489.89 at the end of 2022, representing a decrease of approximately 2.2%[14] - The total liabilities decreased to ¥97,010,877.23 from ¥102,979,220.43, showing a reduction of about 5.8%[15] - The company's accounts payable increased to ¥55,293,201.25 from ¥50,225,934.21, reflecting an increase of approximately 10.4%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,185[9] - The largest shareholder, PAN KE, holds 22.71% of the shares, totaling 129,465,348 shares[9] Cash Flow - The company reported a net cash flow from operating activities of -CNY 76,863,840.88[4] - Cash flow from operating activities for Q1 2023 was -¥76,863.84 million, compared to -¥69,229.46 million in Q1 2022, indicating a deeper cash outflow[20] - Cash inflow from investment activities in Q1 2023 was ¥1,389.81 million, a substantial increase from ¥196.37 million in Q1 2022[20] - The net cash flow from investing activities was $559,216,797.24, a significant improvement compared to a net outflow of $1,957,022,505.78 in the previous period[21] - Total cash and cash equivalents at the end of the period reached $1,511,726,466.07, up from $1,029,512,600.84 at the beginning of the period[21] Other Financial Metrics - The total equity remained stable at ¥570,000,000.00, unchanged from the previous period[15] - The company reported a foreign exchange gain of ¥8,121.43 million in Q1 2023, compared to ¥6,334.97 million in Q1 2022, indicating an increase of about 28%[18] - The company has not reported any significant new product developments or market expansions during this quarter[12] - The company plans to continue focusing on market expansion and new product development to drive future growth[19] - The impact of exchange rate changes on cash and cash equivalents was $2,800,356.94[21] - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[21]

证券代码：688176 证券简称：亚虹医药 公告编号：2023-012 江苏亚虹医药科技股份有限公司 关于召开2022 年度暨2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 5 月 8 日（星期一）至 5 月 12 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 securities@asieris.cn 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 15 日上午 10:00-11:30 （二）会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2023 年 4 月 18 日 发布公司 2022 年度报告 ...

Financial Performance - The net profit attributable to the parent company for 2022 was -246.59 million yuan, with a net profit of -310.09 million yuan after deducting non-recurring gains and losses[4]. - The cumulative undistributed losses as of December 31, 2022, amounted to -644.52 million yuan, primarily due to significant R&D investments in innovative drug development[4]. - The net profit attributable to shareholders of the listed company for 2022 was -246,593,608.24 RMB, a decrease compared to -234,949,267.02 RMB in 2021, reflecting a worsening performance year-over-year[25]. - The basic earnings per share for 2022 was -0.43 RMB, slightly improved from -0.51 RMB in 2021[26]. - The total assets decreased by 7.26% from 3,098,857,157.88 RMB in 2021 to 2,873,779,489.89 RMB in 2022[25]. - The cash flow from operating activities showed a net outflow of -241,960,907.88 RMB, compared to -171,515,933.64 RMB in the previous year, indicating increased cash burn[25]. - The company reported a significant increase in net losses, primarily due to ongoing investments in new drug development and strengthening of the R&D team[26]. - The total equity attributable to shareholders decreased by 8.03% from 3,012,881,818.21 RMB in 2021 to 2,770,800,269.46 RMB in 2022[25]. - The company reported a significant increase in sales expenses, which reached CNY 14,585,877.57, a 314.92% rise from CNY 3,515,363.75, attributed to the expansion of the commercialization team[119]. - The company is facing risks related to insufficient operating funds, which may impact the progress of drug commercialization if external financing is not secured[110]. Research and Development - R&D expenses for the year were 243.89 million yuan, representing a 27.86% increase compared to the previous year[5]. - Future R&D investments are expected to remain at a high level, with significant uncertainty regarding the commercialization of products post-approval[4]. - The company is currently conducting 12 ongoing projects for 9 products, focusing on urogenital system tumors and other major diseases[36]. - APL-1202, a first-in-class oral MetAP2 inhibitor, is in pivotal Phase III trials for non-muscle invasive bladder cancer (NMIBC), with recruitment affected by macroeconomic conditions[36]. - The company is focusing on integrated diagnostic and therapeutic solutions to address unmet clinical needs in bladder cancer management[42]. - The company has established a comprehensive R&D system covering drug discovery, preclinical development, pharmaceutical research, translational science, clinical trials, and regulatory submissions, supported by proprietary technology platforms such as TIMN, PADD, and FASTac[71]. - The company has developed multiple R&D technology platforms, including TIMN, PADD, and FASTac, focusing on targeted immunotherapy and drug delivery systems[78]. - The company is exploring the combination of protein degradation technology with other drug development technologies, such as ADC technology, to enhance competitiveness[79]. - The company has 9 main products and 12 projects in the research pipeline, focusing on unmet clinical needs in the urogenital system and other major diseases[50]. - The company is heavily investing in R&D, which has led to a significant increase in net losses year-on-year, primarily due to ongoing new drug development projects[102]. Market and Product Development - The company is actively engaged in the development of new drugs, including PD-1 monoclonal antibodies, which have received approval from the National Medical Products Administration for treating urothelial carcinoma-related indications[16]. - The company plans to expand its market presence through strategic partnerships and collaborations, aiming to enhance its product pipeline and increase market share in the oncology sector[16]. - The company has outlined a future outlook that includes continued investment in research and development, with a specific focus on innovative treatment options for bladder cancer[16]. - The company is exploring potential mergers and acquisitions to bolster its capabilities and expand its therapeutic offerings in the oncology market[16]. - The company is focusing on new product development, with an investment of $50 million allocated for R&D in the upcoming year[200]. - The company aims to increase its market share by 10% through aggressive marketing strategies[200]. - The company is considering strategic acquisitions to enhance its market position, targeting companies with a combined revenue of $200 million[200]. Risks and Challenges - There is a risk of continued unprofitability and increasing cumulative losses due to high R&D costs and uncertainties in product commercialization[6]. - The company faces risks related to clinical trial progress and outcomes, which may not meet expectations, potentially delaying product approvals[6]. - The company lacks experience in product commercialization and has not yet established a complete marketing team, which poses risks to the successful market launch of its drugs[107]. - The company may face challenges in passing production inspections for its pipeline products, which could delay or prevent market approval[108]. - The company is exposed to risks related to the supply of R&D services and materials, which could increase operational costs and affect profitability if prices rise significantly[109]. - The company faces risks from rapid technological changes and competition from major pharmaceutical and biotech companies, which could impact the commercial viability of its existing and pipeline products[103]. Governance and Management - The company has established a governance structure that includes a board of directors, supervisory board, and various committees to ensure effective management and compliance[193]. - The company has appointed several new board members and executives, enhancing its leadership team[200]. - The company’s management team includes individuals with extensive experience in the pharmaceutical and healthcare sectors, enhancing its strategic capabilities[199]. - The company is focused on maintaining transparency in its financial reporting and governance practices[199]. Future Outlook - The company has set ambitious performance guidance for the upcoming fiscal year, projecting further revenue growth driven by new product launches and market expansion efforts[16]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year[200]. - The company is focusing on international expansion, which may be affected by changes in global political and economic conditions, as well as regulatory environments[116].

证券代码：688176 证券简称：亚虹医药 江苏亚虹医药科技股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | --- | --- | --- | |------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-------|----------| | | | | | | | | □√特定对象调研 □分析师会议 | | | | | 投资者关系活 | □媒体采访 □业绩说明会 | | | | | 动类别 | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 | （请文字说明其他活动内容） | | | | | | 西部证券：李梦圆、程苏恒、何敏秀、曹泽 ...

证券代码：688176 证券简称：亚虹医药 江苏亚虹医药科技股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | --- | |-----------------------------|--------------------------------------------------------------|------------------------------|-------|-------| | | | | | | | 投 资 者关 系 活 | □√特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | | | | 动类别 | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 | （请文字说明其他活动内容） | | | | | 中信证券：甘坛焕 | | | | | | 广发基金：孙琳 | | | | | | 国盛医药：胡偌碧、刘若璠、宋歌 | | | | | | 东财基金：孙辰阳 | | | | | | 安信基金：陈卫国 | | | | | | 嘉实基金：邓云龙 | | | | | 参 与 ...